Cargando…
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
Intracellular antibodies are valuable tools for target validation studies for clinical situations such as cancer. Recently we have shown that antibodies can be used for drug discovery in screening for chemical compounds surrogates by showing that compounds could be developed to the so-called undrugg...
Autores principales: | Tanaka, Tomoyuki, Thomas, Jemima, Van Montfort, Rob, Miller, Ami, Rabbitts, Terry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814043/ https://www.ncbi.nlm.nih.gov/pubmed/33462327 http://dx.doi.org/10.1038/s41598-021-81262-z |
Ejemplares similares
-
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
por: Cruz-Migoni, Abimael, et al.
Publicado: (2019) -
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Quevedo, Camilo E., et al.
Publicado: (2018) -
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, Nicolas, et al.
Publicado: (2018) -
Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, Nicolas, et al.
Publicado: (2018) -
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins
por: Leach, Adam, et al.
Publicado: (2021)